ResearchMoz

Spinal Cord Partnering 2007-2012

Publisher Name » Current Partnering
Published Date » 2012-06-01
No. Of Pages » 100
The Spinal Cord Partnering 2007-2012 provides understanding and access to the spinal cord partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of spinal cord disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors spinal cord technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.

This data driven report contains over 70 links to online copies of actual spinal cord deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

The initial chapters of this report provide an orientation of spinal cord partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in spinal cord partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading pain deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of spinal cord partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of spinal cord technologies and products.

Report scope

Spinal Cord Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to spinal cord trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in spinal cord dealmaking in the biopharma industry since 2007
Access to summary headline, upfront, milestone and royalty data
The leading spinal cord deals by value since 2007


In Spinal Cord Partnering 2007-2012, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in spinal cord partnering

2.1. Introduction
2.2. Spinal cord partnering over the years
2.3. Bigpharma spinal cord dealmaking activity
2.4. Spinal cord partnering by deal type
2.5. Spinal cord partnering industry sector
2.6. Spinal cord partnering by stage of development
2.7. Spinal cord partnering by technology type
2.8. Disclosed financial deal terms for spinal cord partnering
2.8.1 Spinal cord headline values
2.8.2 Spinal cord upfront payments
2.8.3 Spinal cord milestone payments
2.8.4 Spinal cord royalty rates
Chapter 3 Leading spinal cord deals

3.1. Introduction
3.2. Top spinal cord deals by value
3.3. Top spinal cord deals involving bigpharma
Chapter 4 Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines
Chapter 5 Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendices

Appendix 1 Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form Reports
Table of figures

Figure 1: Spinal cord partnering since 2007
Figure 2: Bigpharma top 50 spinal cord deals 2007 to 2011
Figure 3: Bigpharma spinal cord deal frequency 2007 to 2011
Figure 4: Spinal cord partnering by deal type since 2007
Figure 5: Spinal cord partnering by industry sector since 2007
Figure 6: Spinal cord partnering by stage of development since 2007
Figure 7: Spinal cord partnering by technology type since 2007
Figure 8: Spinal cord deals with a headline value
Figure 9: Spinal cord deals with upfront payment values
Figure 10: Spinal cord deals with milestone payments
Figure 11: Spinal cord deals with royalty rates, %
Figure 12: Top spinal cord deals by value since 2007
Figure 13: Top Spinal cord deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions

List of Tables

NA

List of Figures

NA

Upcoming Reports:

Food Traceability Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
  Traceability, a concept which has been in existence for a long time, which was limited to secret services of areas involving high risks or net worth, has seen a rise in application in the food safety and quality industry. Every step of logistics, right from packaging to the end consumer, now uses different techniques of food traceability for varied reasons. However, the core driver of the market has been the growing importance of the ability to track any food item to its origin. This is due to the rise in incidences of food borne diseases and outbreaks and due to complex...
Autologous Cell Therapy Market - Global Forecast, Market Share, Size, Growth and Industry Analysis, 2011-2018
By - Transparency Market Research
Autologous cell therapy is a therapeutic procedure which uses the cells of an individual, which are well-bred and nurtured outside the body and then reintroduced at the site of the disease of the individual. Autologous cell therapy is a new breakthrough in the field of medical history. Autologous cell therapy (ACT) is one of the most rapidly evolving fields due to the revolution in the bioengineering sector since the last few decades.  Previously diseases like Alzheimer’s, Parkinson's were thought to be incurable; however the invention of Autologous cell therapy...
Dried Processed Food Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts, 2012 - 2018
By - Transparency Market Research
The dried processed food market is growing in demand mainly because of the comparatively low prices, easy storage, and high nutritional values. Rice and dried pasta are the largest segments of the dried processed food industry, thereby having strong influence on the performance of the overall market. This market has emerged rapidly during the period of economic recession due to the following reasons: Dried processed food can be stored for a longer time  Low price as compared to non-processed food Despite the economy getting stable, demand for dried processed...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012  
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012  
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples. The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012  
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
Battling against flu, vaccination necessary for health workers
Sep 14, 2012  
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease. Health officials...
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012  
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...